Episode 18

May 13, 2025

00:25:14

18: UGGT1-CDG: Bi-allelic UGGT1 variants and a new congenital disorder of glycosylation

Hosted by

Gustavo B Barra
18: UGGT1-CDG: Bi-allelic UGGT1 variants and a new congenital disorder of glycosylation
Base by Base
18: UGGT1-CDG: Bi-allelic UGGT1 variants and a new congenital disorder of glycosylation

May 13 2025 | 00:25:14

/

Show Notes

Dardas Z et al., The American Journal of Human Genetics - This episode reviews Dardas et al. (2025), which identifies bi-allelic UGGT1 variants in 15 affected individuals as the cause of a distinct congenital disorder of glycosylation (UGGT1-CDG), describes the clinical spectrum, and dissects diverse molecular mechanisms that impair UGGT1 function. Key terms: UGGT1, congenital disorder of glycosylation, neurodevelopmental disorder, glucosyltransferase, ER quality control.

Study Highlights:
Fifteen individuals from ten unrelated families were shown to harbor bi-allelic UGGT1 variants associated with a variable multisystem phenotype dominated by global developmental delay, intellectual disability, seizures, dysmorphic facial features, and frequent microcephaly. Functional studies demonstrated that pathogenic variants impair UGGT1 glucosyltransferase catalytic activity, disrupt mRNA splicing, or abrogate ER retention causing extracellular secretion. Genotype–phenotype correlations indicate that bi-allelic loss-of-function alleles associate with greater severity, including infant death, whereas hypomorphic alleles permit survival with neurodevelopmental disability. Standard transferrin testing was often normal, highlighting the need for genetic testing when clinical suspicion for a CDG is high.

Conclusion:
Bi-allelic UGGT1 variants define UGGT1-CDG, a clinically variable N-linked glycosylation disorder in which distinct molecular mechanisms—loss of catalytic activity, splicing disruption, or loss of ER retention—compromise ER quality control and underlie neurologic and multisystem disease; genetic testing is recommended when CDG is suspected as transferrin assays may be normal.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-13.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 5
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- UGGT1-CDG is caused by bi-allelic UGGT1 variants (15 individuals from 10 families).
- Pathogenic UGGT1 variants impair glucosyltransferase activity, disrupt splicing, or inhibit ER retention.
- Transferrin testing may be normal; genetic testing is essential for diagnosis.
- Arg1546* UGGT1 variant represents an Arab founder variant with a shared haplotype.
- Survival beyond infancy is possible with hypomorphic (missense) UGGT1 variants; null alleles associated with more severe outcomes including perinatal death.
- Total UGGT1-CDG cases described

QC result: Pass.

Other Episodes